CCL21 is an effective surgical neoadjuvant for treatment of mammary tumors

Abdelkader E. Ashour, Xuede Lin, Xiaojian Wang, Heth R. Turnquist, Nicole M. Burns, Amit Tuli, Anguraj Sadanandam, Khaled Suleiman, Rakesh K Singh, James E Talmadge, Joyce C Solheim

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

In previous studies, the chemokine CCL21 has shown biological activities that include T cell, natural killer (NK) cell, and dendritic cell (DC) chemoattraction. The goal of this study was to determine the effects of administering CCL21 to orthotopic mammary tumors in terms of impact on tumor growth rate, immune cell infiltration of the primary tumor, and survival. We found that a single intratumoral administration of CCL21 slowed the growth of orthotopic mammary tumors and increased intratumoral infiltration by T cells, NK cells, and DCs. CCL21 intratumoral administration also prolonged the survival of tumor-bearing mice. Furthermore, mice that received intratumoral neoadjuvant CCL21 prior to surgical resection of tumors survived significantly longer than control mice. The surviving neoadjuvant CCL21-treated mice, when challenged again with cl-66, had a significantly slower rate of tumor growth than challenged control mice. Thus, our data indicate that CCL21 treatment prior to mammary tumor resection can significantly prolong survival and increase resistance to subsequent tumor challenge. Overall, our findings suggest that intratumoral administration of CCL21 has potential as a neoadjuvant immunotherapy for breast cancer.

Original languageEnglish (US)
Pages (from-to)1206-1210
Number of pages5
JournalCancer Biology and Therapy
Volume6
Issue number8
StatePublished - Aug 1 2007

Fingerprint

Neoadjuvant Therapy
Breast Neoplasms
Neoplasms
Natural Killer Cells
Chemokine CCL21
Growth
T-Lymphocytes
Immunotherapy
Dendritic Cells

Keywords

  • Breast tumor
  • CCL21
  • Chemokine
  • Neoadjuvant

ASJC Scopus subject areas

  • Molecular Medicine
  • Oncology
  • Pharmacology
  • Cancer Research

Cite this

Ashour, A. E., Lin, X., Wang, X., Turnquist, H. R., Burns, N. M., Tuli, A., ... Solheim, J. C. (2007). CCL21 is an effective surgical neoadjuvant for treatment of mammary tumors. Cancer Biology and Therapy, 6(8), 1206-1210.

CCL21 is an effective surgical neoadjuvant for treatment of mammary tumors. / Ashour, Abdelkader E.; Lin, Xuede; Wang, Xiaojian; Turnquist, Heth R.; Burns, Nicole M.; Tuli, Amit; Sadanandam, Anguraj; Suleiman, Khaled; Singh, Rakesh K; Talmadge, James E; Solheim, Joyce C.

In: Cancer Biology and Therapy, Vol. 6, No. 8, 01.08.2007, p. 1206-1210.

Research output: Contribution to journalArticle

Ashour, AE, Lin, X, Wang, X, Turnquist, HR, Burns, NM, Tuli, A, Sadanandam, A, Suleiman, K, Singh, RK, Talmadge, JE & Solheim, JC 2007, 'CCL21 is an effective surgical neoadjuvant for treatment of mammary tumors', Cancer Biology and Therapy, vol. 6, no. 8, pp. 1206-1210.
Ashour AE, Lin X, Wang X, Turnquist HR, Burns NM, Tuli A et al. CCL21 is an effective surgical neoadjuvant for treatment of mammary tumors. Cancer Biology and Therapy. 2007 Aug 1;6(8):1206-1210.
Ashour, Abdelkader E. ; Lin, Xuede ; Wang, Xiaojian ; Turnquist, Heth R. ; Burns, Nicole M. ; Tuli, Amit ; Sadanandam, Anguraj ; Suleiman, Khaled ; Singh, Rakesh K ; Talmadge, James E ; Solheim, Joyce C. / CCL21 is an effective surgical neoadjuvant for treatment of mammary tumors. In: Cancer Biology and Therapy. 2007 ; Vol. 6, No. 8. pp. 1206-1210.
@article{977f094151cf4c71b8c116af6e833b4f,
title = "CCL21 is an effective surgical neoadjuvant for treatment of mammary tumors",
abstract = "In previous studies, the chemokine CCL21 has shown biological activities that include T cell, natural killer (NK) cell, and dendritic cell (DC) chemoattraction. The goal of this study was to determine the effects of administering CCL21 to orthotopic mammary tumors in terms of impact on tumor growth rate, immune cell infiltration of the primary tumor, and survival. We found that a single intratumoral administration of CCL21 slowed the growth of orthotopic mammary tumors and increased intratumoral infiltration by T cells, NK cells, and DCs. CCL21 intratumoral administration also prolonged the survival of tumor-bearing mice. Furthermore, mice that received intratumoral neoadjuvant CCL21 prior to surgical resection of tumors survived significantly longer than control mice. The surviving neoadjuvant CCL21-treated mice, when challenged again with cl-66, had a significantly slower rate of tumor growth than challenged control mice. Thus, our data indicate that CCL21 treatment prior to mammary tumor resection can significantly prolong survival and increase resistance to subsequent tumor challenge. Overall, our findings suggest that intratumoral administration of CCL21 has potential as a neoadjuvant immunotherapy for breast cancer.",
keywords = "Breast tumor, CCL21, Chemokine, Neoadjuvant",
author = "Ashour, {Abdelkader E.} and Xuede Lin and Xiaojian Wang and Turnquist, {Heth R.} and Burns, {Nicole M.} and Amit Tuli and Anguraj Sadanandam and Khaled Suleiman and Singh, {Rakesh K} and Talmadge, {James E} and Solheim, {Joyce C}",
year = "2007",
month = "8",
day = "1",
language = "English (US)",
volume = "6",
pages = "1206--1210",
journal = "Cancer Biology and Therapy",
issn = "1538-4047",
publisher = "Landes Bioscience",
number = "8",

}

TY - JOUR

T1 - CCL21 is an effective surgical neoadjuvant for treatment of mammary tumors

AU - Ashour, Abdelkader E.

AU - Lin, Xuede

AU - Wang, Xiaojian

AU - Turnquist, Heth R.

AU - Burns, Nicole M.

AU - Tuli, Amit

AU - Sadanandam, Anguraj

AU - Suleiman, Khaled

AU - Singh, Rakesh K

AU - Talmadge, James E

AU - Solheim, Joyce C

PY - 2007/8/1

Y1 - 2007/8/1

N2 - In previous studies, the chemokine CCL21 has shown biological activities that include T cell, natural killer (NK) cell, and dendritic cell (DC) chemoattraction. The goal of this study was to determine the effects of administering CCL21 to orthotopic mammary tumors in terms of impact on tumor growth rate, immune cell infiltration of the primary tumor, and survival. We found that a single intratumoral administration of CCL21 slowed the growth of orthotopic mammary tumors and increased intratumoral infiltration by T cells, NK cells, and DCs. CCL21 intratumoral administration also prolonged the survival of tumor-bearing mice. Furthermore, mice that received intratumoral neoadjuvant CCL21 prior to surgical resection of tumors survived significantly longer than control mice. The surviving neoadjuvant CCL21-treated mice, when challenged again with cl-66, had a significantly slower rate of tumor growth than challenged control mice. Thus, our data indicate that CCL21 treatment prior to mammary tumor resection can significantly prolong survival and increase resistance to subsequent tumor challenge. Overall, our findings suggest that intratumoral administration of CCL21 has potential as a neoadjuvant immunotherapy for breast cancer.

AB - In previous studies, the chemokine CCL21 has shown biological activities that include T cell, natural killer (NK) cell, and dendritic cell (DC) chemoattraction. The goal of this study was to determine the effects of administering CCL21 to orthotopic mammary tumors in terms of impact on tumor growth rate, immune cell infiltration of the primary tumor, and survival. We found that a single intratumoral administration of CCL21 slowed the growth of orthotopic mammary tumors and increased intratumoral infiltration by T cells, NK cells, and DCs. CCL21 intratumoral administration also prolonged the survival of tumor-bearing mice. Furthermore, mice that received intratumoral neoadjuvant CCL21 prior to surgical resection of tumors survived significantly longer than control mice. The surviving neoadjuvant CCL21-treated mice, when challenged again with cl-66, had a significantly slower rate of tumor growth than challenged control mice. Thus, our data indicate that CCL21 treatment prior to mammary tumor resection can significantly prolong survival and increase resistance to subsequent tumor challenge. Overall, our findings suggest that intratumoral administration of CCL21 has potential as a neoadjuvant immunotherapy for breast cancer.

KW - Breast tumor

KW - CCL21

KW - Chemokine

KW - Neoadjuvant

UR - http://www.scopus.com/inward/record.url?scp=39749111336&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=39749111336&partnerID=8YFLogxK

M3 - Article

VL - 6

SP - 1206

EP - 1210

JO - Cancer Biology and Therapy

JF - Cancer Biology and Therapy

SN - 1538-4047

IS - 8

ER -